Betagenon /Balticgruppen Bio AB announces the start of a bridging PK and safety clinical trial of a novel solid pharmaceutical composition of AMPK activator compound O304 STOCKHOLM, Aug. 17, 2020 ...
Please provide your email address to receive an email when new articles are posted on . Poxel SA announced positive results for the phase 2a trial of PXL770 for the treatment of nonalcoholic ...
LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 ...
Isomeranzin (ISM) binds to Gnas, activating adenylyl cyclase and elevating intracellular cAMP levels. This activation ...
“AMPK is a compelling pharmaceutical target and we are encouraged by the outcome of this study. Not only does the data further demonstrate the potential for PXL770 in NASH, the positive effects on DNL ...
Credit: Shutterstock. PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. The Food and Drug Administration (FDA) has granted Fast Track ...
Nephrodi Therapeutics Inc. has entered an agreement with The McQuade Center for Strategic Research and Development LLC (MSRD), a member of the Otsuka family of pharmaceutical companies, to collaborate ...
Most breast cancers utilize the female hormone estrogen to grow, so drug-induced estrogen deprivation is used as a treatment in many patients. However, cancer will recur in one-third of these patients ...
STOCKHOLM, Aug. 17, 2020 /PRNewswire/ -- In previous Phase I and Phase IIa clinical trials in healthy subjects and in type 2 diabetics, the small molecule AMPK activator compound O304 was administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback